Adam Keeney, Ph.D., is Executive Vice President and Head of Corporate Development at Biogen and has served on the Executive Committee since April 2023. Dr. Keeney brings more than 20 years of experience leading R&D, business development and strategy organizations at industry-leading companies within biotech and large pharma, most recently as the Chief Executive Officer of NodThera, a clinical stage biotech company focused on chronic inflammation.
Prior to joining NodThera, Dr. Keeney was at Sanofi where he had responsibility for all of Sanofi Genzyme’s business development activities, including early- and late-stage deals across therapeutic areas and modalities, successfully completing several significant transactions. Previously, Dr. Keeney worked at Johnson & Johnson where he held a number of business development roles with increasing responsibility and started his career at Lundbeck as a discovery scientist.
Dr. Keeney holds a Ph.D. in Neuropharmacology from the University of Nottingham, UK and a BSc (Hons) from the University of Leeds, UK.
Prior to joining NodThera, Dr. Keeney was at Sanofi where he had responsibility for all of Sanofi Genzyme’s business development activities, including early- and late-stage deals across therapeutic areas and modalities, successfully completing several significant transactions. Previously, Dr. Keeney worked at Johnson & Johnson where he held a number of business development roles with increasing responsibility and started his career at Lundbeck as a discovery scientist.
Dr. Keeney holds a Ph.D. in Neuropharmacology from the University of Nottingham, UK and a BSc (Hons) from the University of Leeds, UK.
Speaking In
1:45 PM - 2:45 PM
Wednesday, June 7
